Developer docs
API playgroundTry for free, no card

Search company profiles

Kainos Laboratories

Full company profile

uuid003miy1

Namestring
Kainos Laboratories
Legal namestring
KAINOS Laboratories, Inc.
Websiteurl
kainos.co.jp
Company typeenum
Private
Founded yearint
1975
Descriptiontext

Kainos Laboratories, Inc. (株式会社カイノス) is a Japanese in vitro diagnostic (IVD) reagent manufacturer founded in 1975 and headquartered in Bunkyo-ku, Tokyo, with a manufacturing and R&D campus in Kasama, Ibaraki. The company develops, manufactures, and distributes clinical diagnostic reagents and analyzers across four technology platforms — biochemistry, immunology, genetics (including isothermal NASBA nucleic acid amplification licensed from bioMerieux), and point-of-care immunochromatography — under proprietary brands such as Aqua-auto Kainos, LATECLE, Statmark, Swiftgene, and ADAMTS13-act ELISA. Kainos also holds the exclusive Japanese distribution rights for Grifols SA's blood transfusion testing systems (Erytra analyzers and DG Gel cards), which is a material channel for the firm.

The company sells primarily B2B to Japanese medical laboratories, hospitals, and blood transfusion centers through five regional sales offices (Sapporo, Sendai, Nagoya, Osaka, Hiroshima), supplemented by an online shop (kainos-lab.com) for international research-use reagents. Pricing on disclosed SKUs is at the unit level (e.g., the FGF-23 ELISA Kit at ¥120,000 per 96-test kit). Capital stock is ¥831.4M and headcount was 158 as of April 1, 2026. Following a public tender offer conducted by Flowers Co., Ltd., Kainos was delisted from the Tokyo Stock Exchange Standard Market in June 2026 and became a wholly owned subsidiary of Denka Co., Ltd., transitioning from a publicly traded independent specialist to a private operating unit within the Denka Group.

Short descriptiontext

Kainos Laboratories is a Japanese in vitro diagnostic reagent manufacturer (founded 1975, ~158 employees) serving clinical laboratories, hospitals, and blood banks across four platforms — biochemistry, immunology, genetics, and POCT — and distributing Grifols blood-transfusion equipment in Japan. Now a wholly owned Denka subsidiary.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical diagnostic reagents, in vitro diagnostics, point-of-care testing, biochemical reagents, blood transfusion testing
Industry2 codes
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Diagnostics / Clinical Diagnostic Reagents
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Reagent Sales
TypeHardware Sales
Description

Development, manufacture, marketing and distribution of pharmaceuticals, diagnostic reagents, and related chemical products. Includes biochemical reagents, immunological reagents, genetic reagents, POCT reagents, controls and calibrators, and COVID-19 test reagents.

kainos.co.jp
2Medical Equipment Sales
TypeHardware Sales
Description

Development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments and medical supplies, including blood transfusion testing equipment from Grifols.

kainos.co.jp
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details1 tier
1FGF-23 ELISA Kit (Cat.# CY-4000) - 96 tests per kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

120,000 JPY per kit (96 tests). FGF-23 Std1 (CY-4053, 80 mL×1) priced at 6,000 JPY. Prices do not include shipping & handling fees.

kainos.co.jp
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1Statmark
Description

Point of care testing (POCT) immunochromatographic reagents for detecting influenza viruses, Group A beta-hemolytic streptococci, and other pathogens.

kainos.co.jp
+5 more records
Core offering1 text field

Kainos Laboratories develops, manufactures, markets, and distributes clinical diagnostic reagents and related medical devices across four technology platforms: biochemistry (Aqua-auto Kainos automated analyzer reagents), immunology (FGF-23 ELISA, LATECLE PCT, ADAMTS13-act ELISA), genetics (NASBA-based Swiftgene molecular diagnostic kits, EXTRAGEN nucleic acid extraction kits), and point-of-care testing (Statmark FLUstick II, Statmark Strep A immunochromatographic tests). The company also serves as the Japan distributor for Grifols SA blood transfusion diagnostic instruments (Erytra/Erytra Eflexis) and DG Gel cards, and sells COVID-19 detection kits, controls, and calibrators to medical laboratories, hospitals, and blood banks.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • High sensitivity FGF-23 detection: minimum detection limit of 3 pg/mL
+2 more records
Product overview1 text field

Kainos Laboratories is an independent Japanese in vitro diagnostic reagent developer and manufacturer established in 1975, operating across four core technology platforms: biochemistry, immunology, genetics, and POCT (Point of Care Testing). The company manufactures and distributes its own branded products (FGF-23 ELISA, LATECLE PCT, ADAMTS13-act ELISA, NASBA kits, Aqua-auto biochemical reagents, Statmark rapid tests) as well as reselling/transacting Grifols (Spain) blood transfusion instruments and reagents under the DG Gel Kainos series. The portfolio includes high-complexity automated reagents (CRE-Ⅳ, ALB, UN-II) for central labs, specialized immunodiagnostic reagents for rare diseases, isothermal molecular diagnostics (NASBA-based Swiftgene products for norovirus, food pathogens), and rapid point-of-care tests (influenza, strep A, COVID-19). The company also distributes third-party products (Nichirei Bio COVID-flu combo, WanTai antibody test) and provides comprehensive quality control materials. Distribution is exclusively B2B through medical distributors; an online shop serves international research reagent customers.

Product and service1 record
1Aqua-auto Kainos CRE-III Test Kit
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-02-01
Description

Capital and business tie-up to further enhance mutual business relationship. Strategic collaboration combining Kainos' diagnostic reagent expertise with Sysmex's broader diagnostics portfolio.

2Gene Therapy Research Institution Co., Ltd.
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-09-01
Description

Capital tie-up by accepting part of third-party allotment of shares to support gene therapy research activities.

kainos.co.jp
3Asahi Kasei Pharma Corporation
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-05-01
Description

Share transfer agreement to further enhance mutual business relationship. Previous technical tie-up agreement in 1993 on clinical examination reagents.

kainos.co.jp
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2011-09-01
Description

Distributorship agreement for blood transfusion diagnostics products. Kainos distributes Grifols products including Erytra automated transfusion testing systems and DG Gel cards in Japan.

Strategic tierHistoricalTypeStrategic or Co-development PartnerAnnounced on2005-07-01
Description

Joint venture agreement for blood banking business. Kainos BB, Co. Ltd. was spun out and renamed Immucor-Kainos, Inc. through joint venture. Stocks later transferred entirely to Immucor, Inc. in May 2008.

6Nichirei Corporation (currently Nichirei Bioscience Inc.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2004-11-01
Description

Joint development of influenza detection reagent 'Statmark Influenza A/B'. Kainos contributed NASBA and immunochromatography technology while Nichirei provided complementary capabilities.

kainos.co.jp
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2000-10-01
Description

License agreement for NASBA (Nucleic Acid Sequence-Based Amplification) Patents. Ownership of the NASBA Gene Amplification patent was transferred from Organon Teknika B.V. to bioMerieux. Kainos also entered a distributorship agreement for genetic products with bioMerieux Japan in May 2004.

Strategic tierHistoricalTypeTechnology or IntegrationAnnounced on1992-09-01
Description

Technical tie-up agreement on clinical examination reagents.

9Nippon Kayaku Co., Ltd.
Strategic tierHistoricalTypeTechnology or IntegrationAnnounced on1987-06-01
Description

Technical tie-up agreement on clinical examination reagents.

kainos.co.jp
10Hitachi Chemical Co., Ltd. (Currently Hitachi Chemical Diagnostics Systems Co., Ltd.)
Strategic tierHistoricalTypeTechnology or IntegrationAnnounced on1981-04-01
Description

Technical tie-up agreement on reagents for clinical analysis equipment.

kainos.co.jp
11Mitsui Pharmaceutical Industry Co. (Currently Bayer Yakuhin, Ltd.)
Strategic tierHistoricalTypeTechnology or IntegrationAnnounced on1976-12-01
Description

Technical tie-up on enzyme immunoassay method (EIA) established in 1976.

kainos.co.jp
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Eiken Chemical Co., Ltd.
TypeDirect peer
Description

Japanese IVD reagent manufacturer with comparable footprint across clinical chemistry, immunology, and molecular diagnostics. Both firms develop and sell proprietary reagent kits for Japanese clinical laboratories and serve overlapping customer segments in hospital and commercial lab channels.

TypeBroad incumbent
Description

French global IVD and microbiology diagnostics major. Kainos licenses NASBA patents from bioMérieux and is also a Japan distributor for bioMérieux genetic products, making it both a partner and a comparable in molecular diagnostics reagent development.

TypeBroad incumbent
Description

Spanish global leader in blood transfusion diagnostics. Kainos is Grifols' authorized distributor in Japan for Erytra analyzers and DG Gel cards; the two share a transfusion-diagnostics franchise with comparable reagent portfolios and regulatory positioning.

4Denka Co., Ltd.
TypeBroad incumbent
Description

Parent company of Kainos since June 2026, with adjacent life-sciences and diagnostics businesses. As the acquirer and strategic owner, Denka now shapes Kainos' commercial and R&D direction and serves as both parent and adjacent peer in the Japanese diagnostics market.

5Asahi Kasei Pharma Corporation
TypeBroad incumbent
Description

Japanese pharmaceutical and diagnostics subsidiary of Asahi Kasei. Kainos has a share transfer agreement and long-standing technical tie-up (1993) with Asahi Kasei on clinical examination reagents, and Asahi Kasei competes in adjacent IVD reagent categories.

TypeBroad incumbent
Description

Global leader in hematology and clinical diagnostics with a broad instrument-and-reagent portfolio. Kainos has a capital and business tie-up with Sysmex (2022), and the two collaborate across hematology and clinical chemistry reagent channels in Japan.

7H.U. Group Holdings (formerly SRL / Miraca Holdings)
TypeDirect peer
Description

Major Japanese clinical diagnostics player operating reference laboratories and a proprietary IVD reagent business (SRL). Comparable in targeting Japanese hospitals and clinical labs with specialty testing menus and offering both diagnostic services and reagent products.

8Nichirei Bioscience Inc.
TypeDirect peer
Description

Japanese bioscience and diagnostics firm that jointly developed the Statmark Influenza A/B reagent with Kainos. Both companies serve Japanese clinical and research customers with immunological and molecular biology reagent kits, and Nichirei distributes Kainos-developed combo products.

9Fujirebio Holdings (H.U. Group)
TypeDirect peer
Description

Japanese in vitro diagnostics specialist with strong chemiluminescent immunoassay and rare-disease testing franchises. Comparable to Kainos in targeting specialty diagnostic niches with proprietary reagent kits reimbursed under Japan's national insurance system.

10Toyobo Co., Ltd. (Diagnostics)
TypeDirect peer
Description

Japanese life-sciences company with a clinical diagnostics reagent business (enzyme diagnostics, immunoassays). Comparable as a Japan-based IVD reagent manufacturer serving hospitals and clinical labs with similar product categories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kainos Laboratories

In Vitro Diagnostics / Clinical Diagnostic Reagentskainos.co.jp

Kainos Laboratories is a Japanese in vitro diagnostic reagent manufacturer (founded 1975, ~158 employees) serving clinical laboratories, hospitals, and blood banks across four platforms — biochemistry, immunology, genetics, and POCT — and distributing Grifols blood-transfusion equipment in Japan. Now a wholly owned Denka subsidiary.

What Kainos Laboratories does

Kainos Laboratories, Inc. (株式会社カイノス) is a Japanese in vitro diagnostic (IVD) reagent manufacturer founded in 1975 and headquartered in Bunkyo-ku, Tokyo, with a manufacturing and R&D campus in Kasama, Ibaraki. The company develops, manufactures, and distributes clinical diagnostic reagents and analyzers across four technology platforms — biochemistry, immunology, genetics (including isothermal NASBA nucleic acid amplification licensed from bioMerieux), and point-of-care immunochromatography — under proprietary brands such as Aqua-auto Kainos, LATECLE, Statmark, Swiftgene, and ADAMTS13-act ELISA. Kainos also holds the exclusive Japanese distribution rights for Grifols SA's blood transfusion testing systems (Erytra analyzers and DG Gel cards), which is a material channel for the firm.

The company sells primarily B2B to Japanese medical laboratories, hospitals, and blood transfusion centers through five regional sales offices (Sapporo, Sendai, Nagoya, Osaka, Hiroshima), supplemented by an online shop (kainos-lab.com) for international research-use reagents. Pricing on disclosed SKUs is at the unit level (e.g., the FGF-23 ELISA Kit at ¥120,000 per 96-test kit). Capital stock is ¥831.4M and headcount was 158 as of April 1, 2026. Following a public tender offer conducted by Flowers Co., Ltd., Kainos was delisted from the Tokyo Stock Exchange Standard Market in June 2026 and became a wholly owned subsidiary of Denka Co., Ltd., transitioning from a publicly traded independent specialist to a private operating unit within the Denka Group.

Kainos Laboratories firmographics

Firmographics
Name
Kainos Laboratories
Legal name
KAINOS Laboratories, Inc.
Website
https://kainos.co.jp
Company type
Private
Founded year
1975
Operating status
Acquired
Headcount range
101–250 employees
Short description
Kainos Laboratories is a Japanese in vitro diagnostic reagent manufacturer (founded 1975, ~158 employees) serving clinical laboratories, hospitals, and blood banks across four platforms — biochemistry, immunology, genetics, and POCT — and distributing Grifols blood-transfusion equipment in Japan. Now a wholly owned Denka subsidiary.
Ownership category
akta.pro rank

Kainos Laboratories industry classification

Industry
Product category
In Vitro Diagnostics / Clinical Diagnostic Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAAAM
IVD Reagents, Assay Kits & Consumables (Non-instrument)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Clinical diagnostic reagents
  • In vitro diagnostics
  • Point-of-care testing
  • Biochemical reagents
  • Blood transfusion testing

Where Kainos Laboratories is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices7 records

Markets served

Kainos Laboratories business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Diagnostic Reagent Sales: Development, manufacture, marketing and distribution of pharmaceuticals, diagnostic reagents, and related chemical products. Includes biochemical reagents, immunological reagents, genetic reagents, POCT reagents, controls and calibrators, and COVID-19 test reagents.
  2. Medical Equipment Sales: Development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments and medical supplies, including blood transfusion testing equipment from Grifols.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFGF-23 ELISA Kit (Cat.# CY-4000) - 96 tests per kit

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Kainos Laboratories product offering

Product offering

Core offering

Kainos Laboratories develops, manufactures, markets, and distributes clinical diagnostic reagents and related medical devices across four technology platforms: biochemistry (Aqua-auto Kainos automated analyzer reagents), immunology (FGF-23 ELISA, LATECLE PCT, ADAMTS13-act ELISA), genetics (NASBA-based Swiftgene molecular diagnostic kits, EXTRAGEN nucleic acid extraction kits), and point-of-care testing (Statmark FLUstick II, Statmark Strep A immunochromatographic tests). The company also serves as the Japan distributor for Grifols SA blood transfusion diagnostic instruments (Erytra/Erytra Eflexis) and DG Gel cards, and sells COVID-19 detection kits, controls, and calibrators to medical laboratories, hospitals, and blood banks.

Product overview

Kainos Laboratories is an independent Japanese in vitro diagnostic reagent developer and manufacturer established in 1975, operating across four core technology platforms: biochemistry, immunology, genetics, and POCT (Point of Care Testing). The company manufactures and distributes its own branded products (FGF-23 ELISA, LATECLE PCT, ADAMTS13-act ELISA, NASBA kits, Aqua-auto biochemical reagents, Statmark rapid tests) as well as reselling/transacting Grifols (Spain) blood transfusion instruments and reagents under the DG Gel Kainos series. The portfolio includes high-complexity automated reagents (CRE-Ⅳ, ALB, UN-II) for central labs, specialized immunodiagnostic reagents for rare diseases, isothermal molecular diagnostics (NASBA-based Swiftgene products for norovirus, food pathogens), and rapid point-of-care tests (influenza, strep A, COVID-19). The company also distributes third-party products (Nichirei Bio COVID-flu combo, WanTai antibody test) and provides comprehensive quality control materials. Distribution is exclusively B2B through medical distributors; an online shop serves international research reagent customers.

Differentiator

Problem solved

Functional benefit

Brands

  • Statmark: Point of care testing (POCT) immunochromatographic reagents for detecting influenza viruses, Group A beta-hemolytic streptococci, and other pathogens.
  • Swiftgene
  • Aqua-auto Kainos
  • LATECLE
  • EXTRAGEN
  • DG Gel

Products and services

  • Aqua-auto Kainos CRE-III Test Kit

Quantifiable outcome

  • High sensitivity FGF-23 detection: minimum detection limit of 3 pg/mL
  • +2 more outcomes

Companies that use Kainos Laboratories

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Kainos Laboratories technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Kainos Laboratories partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered major, minor, core and historical.

  • Sysmex CorporationmajorStrategic or Co-development Partner · 1 February 2022Capital and business tie-up to further enhance mutual business relationship. Strategic collaboration combining Kainos' diagnostic reagent expertise with Sysmex's broader diagnostics portfolio.
  • Gene Therapy Research Institution Co., Ltd.minorStrategic or Co-development Partner · 1 September 2020Capital tie-up by accepting part of third-party allotment of shares to support gene therapy research activities.
  • Asahi Kasei Pharma CorporationmajorStrategic or Co-development Partner · 1 May 2019Share transfer agreement to further enhance mutual business relationship. Previous technical tie-up agreement in 1993 on clinical examination reagents.
  • Grifols SAcoreChannel Partner/ Reseller/ Distributor · 1 September 2011Distributorship agreement for blood transfusion diagnostics products. Kainos distributes Grifols products including Erytra automated transfusion testing systems and DG Gel cards in Japan.
  • Immucor, Inc.historicalStrategic or Co-development Partner · 1 July 2005Joint venture agreement for blood banking business. Kainos BB, Co. Ltd. was spun out and renamed Immucor-Kainos, Inc. through joint venture. Stocks later transferred entirely to Immucor, Inc. in May 2008.
  • Nichirei Corporation (currently Nichirei Bioscience Inc.)coreStrategic or Co-development Partner · 1 November 2004Joint development of influenza detection reagent 'Statmark Influenza A/B'. Kainos contributed NASBA and immunochromatography technology while Nichirei provided complementary capabilities.
  • bioMerieuxcoreTechnology or Integration · 1 October 2000License agreement for NASBA (Nucleic Acid Sequence-Based Amplification) Patents. Ownership of the NASBA Gene Amplification patent was transferred from Organon Teknika B.V. to bioMerieux. Kainos also entered a distributorship agreement for genetic products with bioMerieux Japan in May 2004.
  • Kyowa Kirin Co., Ltd. (formerly Kirin Beer Co., Ltd.)historicalTechnology or Integration · 1 September 1992Technical tie-up agreement on clinical examination reagents.
  • Nippon Kayaku Co., Ltd.historicalTechnology or Integration · 1 June 1987Technical tie-up agreement on clinical examination reagents.
  • Hitachi Chemical Co., Ltd. (Currently Hitachi Chemical Diagnostics Systems Co., Ltd.)historicalTechnology or Integration · 1 April 1981Technical tie-up agreement on reagents for clinical analysis equipment.
  • Mitsui Pharmaceutical Industry Co. (Currently Bayer Yakuhin, Ltd.)historicalTechnology or Integration · 1 December 1976Technical tie-up on enzyme immunoassay method (EIA) established in 1976.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Kainos Laboratories competitors and assessment

Company assessment

Direct peers

  • Eiken Chemical Co., Ltd. Japanese IVD reagent manufacturer with comparable footprint across clinical chemistry, immunology, and molecular diagnostics. Both firms develop and sell proprietary reagent kits for Japanese clinical laboratories and serve overlapping customer segments in hospital and commercial lab channels.
  • H.U. Group Holdings (formerly SRL / Miraca Holdings): Major Japanese clinical diagnostics player operating reference laboratories and a proprietary IVD reagent business (SRL). Comparable in targeting Japanese hospitals and clinical labs with specialty testing menus and offering both diagnostic services and reagent products.
  • Nichirei Bioscience Inc. Japanese bioscience and diagnostics firm that jointly developed the Statmark Influenza A/B reagent with Kainos. Both companies serve Japanese clinical and research customers with immunological and molecular biology reagent kits, and Nichirei distributes Kainos-developed combo products.
  • Fujirebio Holdings (H.U. Group): Japanese in vitro diagnostics specialist with strong chemiluminescent immunoassay and rare-disease testing franchises. Comparable to Kainos in targeting specialty diagnostic niches with proprietary reagent kits reimbursed under Japan's national insurance system.
  • Toyobo Co., Ltd. (Diagnostics): Japanese life-sciences company with a clinical diagnostics reagent business (enzyme diagnostics, immunoassays). Comparable as a Japan-based IVD reagent manufacturer serving hospitals and clinical labs with similar product categories.

Broad incumbents

  • bioMérieux SA: French global IVD and microbiology diagnostics major. Kainos licenses NASBA patents from bioMérieux and is also a Japan distributor for bioMérieux genetic products, making it both a partner and a comparable in molecular diagnostics reagent development.
  • Grifols SA: Spanish global leader in blood transfusion diagnostics. Kainos is Grifols' authorized distributor in Japan for Erytra analyzers and DG Gel cards; the two share a transfusion-diagnostics franchise with comparable reagent portfolios and regulatory positioning.
  • Denka Co., Ltd. Parent company of Kainos since June 2026, with adjacent life-sciences and diagnostics businesses. As the acquirer and strategic owner, Denka now shapes Kainos' commercial and R&D direction and serves as both parent and adjacent peer in the Japanese diagnostics market.
  • Asahi Kasei Pharma Corporation: Japanese pharmaceutical and diagnostics subsidiary of Asahi Kasei. Kainos has a share transfer agreement and long-standing technical tie-up (1993) with Asahi Kasei on clinical examination reagents, and Asahi Kasei competes in adjacent IVD reagent categories.
  • Sysmex Corporation: Global leader in hematology and clinical diagnostics with a broad instrument-and-reagent portfolio. Kainos has a capital and business tie-up with Sysmex (2022), and the two collaborate across hematology and clinical chemistry reagent channels in Japan.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Kainos Laboratories compliance and trust

Trust signal

Compliance2 records

Kainos Laboratories financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kainos Laboratories leadership team

Management profile

Number of profiles

Profiles8 records

Kainos Laboratories subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Kainos Laboratories funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kainos Laboratories M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kainos Laboratories

What does Kainos Laboratories do?

Kainos Laboratories develops, manufactures, markets, and distributes clinical diagnostic reagents and related medical devices across four technology platforms: biochemistry (Aqua-auto Kainos automated analyzer reagents), immunology (FGF-23 ELISA, LATECLE PCT, ADAMTS13-act ELISA), genetics (NASBA-based Swiftgene molecular diagnostic kits, EXTRAGEN nucleic acid extraction kits), and point-of-care testing (Statmark FLUstick II, Statmark Strep A immunochromatographic tests). The company also serves as the Japan distributor for Grifols SA blood transfusion diagnostic instruments (Erytra/Erytra Eflexis) and DG Gel cards, and sells COVID-19 detection kits, controls, and calibrators to medical laboratories, hospitals, and blood banks.

Is Kainos Laboratories a public or private company?

Kainos Laboratories is a private company. It is classified as corporate owned and is currently acquired.

When was Kainos Laboratories founded?

Kainos Laboratories was founded in 1975. It employs 101 to 250 people.

Where is Kainos Laboratories based?

Kainos Laboratories is headquartered in Tokyo, Japan, in the Asia region.

How does Kainos Laboratories make money?

Two revenue lines are on record. Diagnostic Reagent Sales are the primary driver. The others are medical Equipment Sales.

Who are Kainos Laboratories's main competitors?

Direct peers on record are Eiken Chemical Co., Ltd., H.U. Group Holdings (formerly SRL / Miraca Holdings), Nichirei Bioscience Inc., Fujirebio Holdings (H.U. Group) and Toyobo Co., Ltd. (Diagnostics). Broad incumbents are bioMérieux SA, Grifols SA, Denka Co., Ltd., Asahi Kasei Pharma Corporation and Sysmex Corporation.

Does Kainos Laboratories have an API?

No public API is recorded for Kainos Laboratories.

What industry is Kainos Laboratories in?

Kainos Laboratories's product category is In Vitro Diagnostics / Clinical Diagnostic Reagents. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals